DGAP-News
MeVis Medical Solutions AG: Successful start into the new fiscal year
DGAP-News: MeVis Medical Solutions AG / Key word(s): Interim Report/Quarter Results One-time effect contributes significantly to the very strong sales |
- Revenues with EUR 5.5 million 36 % above prior year
-
- Including one-time effect of EUR 1.8 million from the sale of MeVisLab usage rights
-
- Earnings before interest an taxes (EBIT) of EUR 2.9 million
(significantly above prior-year's figure of EUR 0.9 million) -
- EBIT margin of 52 %
-
- Net profit after taxes increased by EUR 0.7 million to EUR 4.4 million
-
Bremen, February 21, 2017 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its figures for the first quarter of fiscal year 2017, with the reporting period October 1 to December 31, 2016.
Sales generated in the first quarter of 2017 amounted to EUR 5.5 million, 36 % higher than the corresponding quarter of the previous year (EUR 4.1 million). The increase in sales resulted mainly from the sale of extensive usage rights for the tool for the development of software prototypes MeVisLab for EUR 1.8 million, which is also included in the revenues of the Other Diagnostics segment. Sales of new licenses fell by 29 % to EUR 1.3 million and the maintenance business decreased by 5 %. Sales in the Digital Mammography segment decreased by 15 % to EUR 2.7 million (prev. year: EUR 3.1 million), sales in the Other Diagnostics segment increased to EUR 2.9 million (prev. year: EUR 1.0 million), without the one-time effect this corresponds to a growth of 11 %.